SPX5,370.64+387.87 7.78%
DIA401.53+25.05 6.65%
IXIC16,782.15+1514.24 9.92%

Piper Sandler Maintains Neutral on Corcept Therapeutics, Raises Price Target to $150

Benzinga·04/03/2025 12:55:30
Listen to the news
Piper Sandler analyst Brian Mullan maintains Corcept Therapeutics (NASDAQ:YUM) with a Neutral and raises the price target from $140 to $150.